Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients: A randomized phase II study

Cancer

Volumn 77, Issue 2, 1996, Pages 344-351

  Petrioli, Roberto ^a   Frediani, Bruno ^a   Manganelli, Antonio ^a   Barbanti, Gabriele ^a   De Capua, Bruno ^a   De Lauretis, Albertina ^a   Salvestrini, Franco ^a   Mondillo, Sergio ^a   Francini, Guido ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Auditory brain stem response; Bladder cancer; Carboplatin; Chemotherapy; Cisplatin; Ototoxicity

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIRUBICIN; METHOTREXATE; METHYLPREDNISOLONE; ONDANSETRON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVOKED BRAIN STEM AUDITORY RESPONSE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; EPIRUBICIN; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 0030023088     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960115)77:2<344::AID-CNCR18>3.0.CO;2-1     Document Type: Review

References (36)

1. Merrin C. Treatment of advanced bladder cancer with cisdiammine-dichloroplatinum II: a pilot study. J Urol 1978; 119:493-5.
2. Peters PC, O'Neill MR. Cis-diamminedichloroplatinum as a therapeutic agent in metastatic transitional cell carcinoma. J Urol 1980;123:375-7.
3. Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 1989;64:2448-58.
4. Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, et al. A prospective randomized trial comparing M-VAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990;8:1050-5.
5. Loehrer PJ Sr., Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10:1066-73.
6. Geller NL, Sternberg CN, Penenberg D, Scher H, Yagoda A. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy. Cancer 1991; 67:1525-31.
7. Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988;318:1414-22.
8. Aso Y, Akaza H. Effect of recombinant human granulocyte colony-stimulating factor in patients receiving chemotherapy for urogenital cancer. Urological rhG-CSF Study Group. J Urol 1992;147:1060-4.
9. Jantunen IT, Muhonen TT, Kataja W, Flander MK, Teerenhovi L. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy. A randomized study. Eur J Cancer 1993;29A:1669-72.
10. Rassweiler J, Rüther U, Bäuerle K, Bub P, Jipp P, Eisenberger F. Polychemotherapie nach dem M-VEC Schema (Methotrexat, Vinblastin, Epirubicin, Cisplatin) beim fortgeschrittenen Harnblasenkarzinom-Effektivität und Toxizität. Urologe A 1989;28:25-30.
11. Frassoldati A, Federico M, Barbieri F, Brausi M, Pollastri C, Bern G. Methotrexate, vinblastine, epidoxorubicin and cisplatin (M-VEC) in patients with locally advanced transitional bladder cancer. Med Oncol Tumor Pharmacother 1991;8:99-103.
12. Trump DL, Elson P, Madajewicz S, Dickman SH, Hahn RG, Harris JE, et al. Randomized phase II evaluation of carboplatin and CHIP in advanced transitional cell carcinoma of the urothelium. J Urol 1990;144:1119-22.
13. Muggia FM. Overview of carboplatin: replacing, complementing, and extending the therapeutic horizons of cisplatin. Semin Oncol 1989;16(S5):7-13.
14. Simon R, Wittes RE, Ellenberg SS. Randomized Phase II clinical trials. Cancer Treat Rep 1985;69:1375-81.
15. Jewett DL, Williston JS. Auditory evoked far fields averaged from the scalp of humans. Brain 1971;94:681-96.
16. Van Oosterom AT, Akaza H, Hall R, Hirao Y, Jones WG, Matsumura Y, et al. Response criteria phase II/phase III invasive bladder cancer. Prog Clin Biol Res 1986;221:301-10.
17. World Health Organization. Handbook for reporting results of cancer treatment. No. 48. Geneva: World Health Organization, 1979.
18. Kaplan EL, Meier P. Non parametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-81.
19. Peto R, Pike MC, Armitage P, Breslaw NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977;35:1-39.
20. Tannock I, Gospodarowicz M, Connolly J, Jewett M. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. J Urol 1989;142:289-92.
21. Scher HI, Geller NL, Curley T, Tao Y. Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC. J Clin Oncol 1993;11:400-7.
22. Francini G, Gonnelli S, Petrioli R, Conti F, Paffetti P, Gennari C. Treatment of bone metastases with dichloromethylene bisphosphonate. J Clin Oncol 1992;10:591-8.
23. Mottet-Auselo N, Bons-Rosset F, Costa P, Louis JF, Navratil H. Carboplatin and urothelial tumors. Oncology 1993; 50(S2):28-36.
24. Bellmunt J, Albanell J, Gallego OS, Ribas A, Vicente P, Carulla J, et al. Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer 1992;70:1974-9.
25. Raabe NK, Fossa SD, Paro G. Phase II study of carboplatin in locally advanced and metastatic transitional cell carcinoma of the urinary bladder. Br J Urol 1989;64:604-7.
26. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
27. Sorensen BT, Strömgren A, Jakobsen P, Jakobsen A. A limited sampling method for estimation of the carboplatin area under the curve. Cancer Chemother Pharmacol 1993;31:324-7.
28. Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, et al. Relationship between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992;10:520-8.
29. Oliver RT, Kwok HK, Highman WI, Waxman J. Methotrexate, cisplatin, and carboplatin as single agents and in combination for metastatic bladder cancer. Br J Urol 1986;58:31-5.
30. Arap W, Scher HI. The value of cytotoxic chemotherapy in locally invasive and metastatic bladder cancer. In: Williams G, Waxman J, editors. Urological Cancer: a consensus. London: Edward Arnold, 1991:185-99.
31. Scher HI, Norton L. Chemotherapy for urothelial tract malignancies: breaking the deadlock. Semin Surg Oncol 1992; 8:316-41.
32. Torti FM, Bristow MM, Lum BL, Carter SK, Howes AE, Aston DA, et al. Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res 1986; 46:3722-7.
33. Laurell G, Jungnelius U. High-dose cispiatin treatment: hearing loss and plasma concentrations. Laryngoscope 1990;100:724-34.
34. Vermorken JB, Kapteijn TS, Hart AA, Pinedo HM. Ototoxicity of cis-diamminedichloroplatinum (II). Influence of dose, schedule and mode of administration. Eur J Cancer Clin Oncol 1983;19:53-8.
35. Fausti SA, Frey RH, Henry JA, Olson DJ, Schaffer HI. Early detection of ototoxicity using high-frequency, tone-burstevoked auditory brainstem responses. J Am Acad Audiol 1992;3:397-404.
36. van der Hulst RJ, Dreschler WA, Urbanus NA. High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. Ann Otol Rhinol Laryngol 1988;97:133-7.